Form 4: Enliven Therapeutics CFO Benjamin Hohl Executes Stock Option Exercises and Sales

Benjamin Hohl, CFO of Enliven Therapeutics, executed stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 4, 2024, Benjamin Hohl, the CFO of Enliven Therapeutics, exercised options to acquire 10,218 shares of common stock at a price of $2.48 per share and sold the same amount at a weighted average price of $27.5082.
• On October 7, 2024, Hohl exercised options to acquire 1,270 shares of common stock at a price of $2.48 per share and sold the same amount at a weighted average price of $27.5081.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns no shares of common stock.
• Hohl still holds options to purchase 180,870 shares of common stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to stock transactions by a company insider. The use of a pre-arranged trading plan suggests no unexpected or unusual activity. Therefore, the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan suggests that these trades were pre-planned and not based on any inside information at the time of the transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider information.

Key Dates